FOXO4-DRI acts as a competitive inhibitor of this interaction binding directly to the transactivation domain 2 (TAD2) of p53, displacing FOXO4, and allowing phosphorylated p53 to be exported from the nucleus and directed to mitochondria, where it activates BAX, triggers caspase-3 cleavage (via the p53/BCL-2/Caspase-3 signalling pathway), and drives cell-intrinsic apoptosis
At 1mg/mL, the unit measurements are five times larger than 5mg/mL
Medical Disclaimer References Wilding, J
From a public health perspective, if we are working to end the opioid crisis and reduce rates of smoking and excess alcohol consumption, we need treatments that can scale to reach a large portion of the affected population
FeelGood's published disclaimers - including "Prescription medications require a virtual consultation and approval by a licensed healthcare provider